This trial will be conducted to study the efficacy and safety of Silodosin in the treatment of female lower urinary tract symptoms.
The double blinded randomized controlled trial will evaluate efficacy and safety of silodosin in treatment of female lower urinary tract symptoms by comparing with placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
278
International Prostate Symptom Score
International Prostate Symptom Score will be recorded for each patient. The score ranged between 7 and 35. Higher scores means worse outcome.
Time frame: 8 weeks
Overactive Bladder Validated 8-question
Overactive Bladder Validated 8-question will be recorded for each patient. The score ranged between 2 and 42. Higher scores means worse outcome.
Time frame: 8 weeks
Uroflometry
Voided volume , Maximum flow, Voiding time, Post void residual
Time frame: 8 weeks
Adverse events
Side effects of the treatment will be recorded
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.